Thalidomide-O-amido-C3-NH2 (TFA) (Synonyms: Cereblon Ligand-Linker Conjugates 16 TFA; E3 Ligase Ligand-Linker Conjugates 52 TFA) |
| Catalog No.GC38095 |
Thalidomide-O-amido-C3-NH2 (TFA) est un conjugué ligand-lieur E3 ligase synthétisé qui incorpore le ligand cereblon à base de thalidomide et un lieur utilisé dans la technologie PROTAC.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2022182-58-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Thalidomide-O-amido-C3-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
[1]. Lohbeck J, et al. Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development. Bioorg Med Chem Lett. 2016 Nov 1;26(21):5260-5262.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *